XML 46 R34.htm IDEA: XBRL DOCUMENT
v3.23.2

Segments of Business (Tables) | 3 Months Ended
--- | ---
Jun. 30, 2023
Segment Reporting [Abstract] |
Schedule of financial information relating to reportable operating segments and reconciliations to the condensed consolidated totals | Financial information relating to the Company’s reportable operating segments and reconciliations to the condensed consolidated totals was as follows:
|  |  | Three Months Ended June 30,
(In millions) |  |  |  |  | 2023 |  | 2022
Segment revenues (1) |  |  |  |  |  |  |
U.S. Pharmaceutical |  |  |  |  | $ | 67,160 |  |  | $ | 56,947 |
Prescription Technology Solutions |  |  |  |  | 1,244 |  |  | 1,066 |
Medical-Surgical Solutions |  |  |  |  | 2,611 |  |  | 2,592 |
International |  |  |  |  | 3,468 |  |  | 6,549 |
Total revenues |  |  |  |  | $ | 74,483 |  |  | $ | 67,154 |
Segment operating profit (loss) (2) |  |  |  |  |  |  |
U.S. Pharmaceutical (3) |  |  |  |  | $ | 827 |  |  | $ | 696 |
Prescription Technology Solutions (4) |  |  |  |  | 231 |  |  | 144 |
Medical-Surgical Solutions |  |  |  |  | 227 |  |  | 256 |
International (5) |  |  |  |  | 57 |  |  | (6) |
Subtotal |  |  |  |  | 1,342 |  |  | 1,090 |
Corporate expenses, net (6) |  |  |  |  | (204) |  |  | (39) |
Interest expense |  |  |  |  | (47) |  |  | (45) |
Income from continuing operations before income taxes |  |  |  |  | $ | 1,091 |  |  | $ | 1,006 |
(1)Revenues from services on a disaggregated basis represent approximately 1% of the U.S. Pharmaceutical segment’s total revenues, less than 37% of the RxTS segment’s total revenues, less than 1% of the Medical-Surgical Solutions segment’s total revenues, and less than 1% of the International segment’s total revenues. The International segment reflects foreign revenues. Revenues for the remaining three reportable segments are derived in the U.S. (2)Segment operating profit (loss) includes gross profit, net of total operating expenses, as well as other income, net, for the Company’s reportable segments. (3)The Company’s U.S. Pharmaceutical segment’s operating profit includes the following: •cash receipts for the Company’s share of antitrust legal settlements of $118 million for the three months ended June 30, 2023; and •a charge of $32 million and a credit of $13 million related to the last-in, first-out (“LIFO”) method of accounting for inventories for the three months ended June 30, 2023 and 2022, respectively. (4)The Company’s RxTS segment’s operating profit for the three months ended June 30, 2023 includes a fair value adjustment gain of $28 million, which reduced the Company’s contingent consideration liability related to the RxSS acquisition, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.” (5)The Company’s International segment’s operating loss for the three months ended June 30, 2022 includes charges of $94 million to remeasure the assets and liabilities of the E.U. disposal group to fair value less costs to sell, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.” (6)Corporate expenses, net includes the following: •restructuring charges of $40 million for the three months ended June 30, 2023 for restructuring initiatives as discussed in more detail in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net;” and •a gain of $106 million for the three months ended June 30, 2022 primarily related to the effect of accumulated other comprehensive loss components from the E.U. disposal group, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.”

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration